Search Medical Condition
Please enter condition
Please choose location

Trafford, United Kingdom Clinical Trials

A listing of Trafford, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (364) clinical trials

A Pragmatic Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (DECIDE Study)

A longitudinal, open labelled, pragmatic randomized 104 week multicentre trial of patients with type 2 diabetes mellitus to evaluate the comparative effectiveness between dapagliflozin and Standard of Care (SOC)

Phase

0.0 miles

Learn More »

Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer

OBJECTIVES: Primary - To determine whether pre-operative treatment of HER-2 positive breast cancer patients with anti-HER2 therapy consisting of trastuzumab (Herceptin®) vs lapatinib ditosylate inhibits proliferation or increases apoptosis. - To compare the effects of trastuzumab (Herceptin®), lapatinib ditosylate and the combination of lapatinib ditosylate and trastuzumab (Herceptin®) on the ...

Phase

3.01 miles

Learn More »

QVA Mechanistic Efficacy Study (Receptor Effects Etc)

Current physiological measures of small airway dysfunction are limited, subject to a high degree of variability and do not allow a quantitative assessment of global and regional ventilation defects. The MRI approach represents an opportunity to better understand the impact of a potent dual bronchodilator on the small and central ...

Phase

3.28 miles

Learn More »

Short-term Preoperative Treatment With Enzalutamide Alone or in Combination With Exemestane in Primary Breast Cancer

This study is being carried out to see if the antiandrogen enzalutamide has antitumour effects in early breast cancer. Enzalutamide blocks the action of androgens on the androgen receptor (AR) and may slow down or stop breast cancers growing. Enzalutamide is approved for the treatment of prostate cancer. The trial ...

Phase

3.28 miles

Learn More »

Longitudinal Follow up to Assess Biomarkers Predictive of Emphysema Progression in Patients With COPD (Chronic Obstructive Pulmonary Disease)

The study will include 60 healthy subjects (ex-smoker without any airflow limitation), 125 COPD GOLD (global initiative for chronic obstructive lung disease) I , 125 COPD GOLD II, 125 COPD GOLD III and up to 20 patients with COPD and A1AT (Alpha1-Antitrypsin) deficiency (ZZ genotype). Soluble and imaging biomarkers will ...

Phase N/A

3.28 miles

Learn More »

K1-70 - A Study in Subjects With Graves' Disease

Graves' disease is one of the most common overt autoimmune disorders. Patients with Graves' disease have thyroid over activity and hyperthyroidism. Symptoms of hyperthyroidism include goitre, fatigue, heat intolerance, sweating, weight loss despite good appetite, shakiness, inappropriate anxiety, palpitations of the heart, shortness of breath, tetchiness and agitation, poor sleep, ...

Phase

3.28 miles

Learn More »

First Time in Human (FTIH) Study to Evaluate Safety Tolerability Immunogenicity Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma

GSK3511294 is a humanized monoclonal antibody antagonist of Interleukin (IL)-5 which is known to block binding of IL-5 to the IL-5 receptor complex, causing a reduction in the circulating population of eosinophils. This is a single ascending dose FTIH study to investigate safety, tolerability, immunogenicity, pharmacokinetics (PK) and pharmacodynamics (PD) ...

Phase

3.28 miles

Learn More »

Repeat Doses of BAY 1817080 in Healthy Males & Proof of Concept in Chronic Cough Patients

To investigate the safety and tolerability of ascending repeated oral doses of BAY1817080 in healthy volunteers(Part1). To investigate the safety, tolerability and efficacy of BAY1817080 in patients with refractory chronic cough(Part2).

Phase

3.28 miles

Learn More »

A Study to Evaluate Safety PK and PD of FDL169 in Cystic Fibrosis Subjects

This is a multicenter, randomized double-blind, placebo-controlled dose-escalation and parallel-arm, dose-ranging study. Enrollment is planned to occur at approximately 14 global sites. Approximately 24 subjects with CF who are homozygous for the F508del-CFTR mutation will be enrolled in two cohorts.

Phase

3.28 miles

Learn More »

BI 443651 Multiple Rising Dose in Healthy Volunteers Followed by a Cross-over in CF Subjects

The objective of this study is to investigate the safety, tolerability, and pharmacokinetics of BI 443651 in male and female healthy volunteers and subjects with Cystic Fibrosis (CF).

Phase

3.28 miles

Learn More »